Phase 3 study in 48 children ≥40 kg with moderately to severely active Crohn's disease: 52.1% achieved clinical remission at week 8 after ustekinumab induction (primary endpoint). Week-52 remission was 60.0% with 12-weekly and 43.5% with 8-weekly dosing (secondary).
RCTn = 48 patients
De Greef et al. Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg